The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
CAR T cells produced in vivo to treat cardiac injury
Open accessAbstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 701–800 of 1,001
Ye, X., Wu, Y., Zhang, H., Shi, L., Zhou, Y., Guo, S., Dong, J., & Cai, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216278 · Cited by 10
Linking immune modulation to cardiac fibrosis
Bengel, F. M., Epstein, J. A., Gropler, R. J., Haberkorn, U., Kramann, R., Lavine, K. J., Leuschner, F., Liu, Y., Rosenthal, N. A., & Wu, H. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00459-3 · Cited by 11
Self-citationThe intertwined aging, the extracellular matrix, and fibrosis
Nyström, A. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00018.2024 · Cited by 10
The RNA delivery dilemma—lipid versus polymer nanoparticle platforms
Martins, C., Mitchell, M. J., Peer, D., Perrie, Y., Siegwart, D. J., Alonso, M. J., & Aparicio-Blanco, J. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02044-6 · Cited by 14
Yang, Q., Jin, J., Sun, J., Zhang, L., Tang, J. B., & Zhou, Y. L. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.10.043 · Cited by 9
Avolio, E., Bassani, B., Campanile, M., Mohammed, K. A. K., Muti, P. C., Bruno, A., Spinetti, G., & Madeddu, P. R. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100033 · Cited by 9
Cell therapies for viral diseases: a new frontier
Nardo, D., Maddox, E. G., & Riley, J. L. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-024-01031-8 · Cited by 10
Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer
Wu, L., Zhu, L., & Chen, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70306 · Cited by 9
Zheng, Y., Wang, Y., & Zhang, X. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02230-x · Cited by 9
Wang, J., Tian, H., Gao, Y., Qiu, X., Bao, Z., Zhao, D., Zhang, F., Zhang, Z., Wang, F., Zheng, S., et al. (2025) · Research · doi:10.34133/research.0808 · Cited by 15
ApoE2-DARPin fusion proteins enable selective RNA transfer to CD8 T cells by lipid nanoparticles
Theuerkauf, S. A., Zinser, L. J., Sheth, N., Adabi, E., Knapp, L. R., Gorol, J. M., Hein, S., Chroni, A., Thalheimer, F. B., & Buchholz, C. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114377 · Cited by 11
Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
Sioud, M., & Casey, N. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020909 · Cited by 11
A material toolbox for engineering targeted lipid nanoparticles for RNA therapies
Yoo, S., Ang, M. J. Y., Murray, A. M., & Mitchell, M. J. (2026) · Materials Today · doi:10.1016/j.mattod.2025.12.034 · Cited by 10
Cardiotoxicity of T cell immunotherapies
Raddatz, M. A., Stein-Merlob, A. F., Mahmood, S. S., Ganatra, S., Addison, D., Lin, T. L., Larson, S. M., & Yang, E. H. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01265-z · Cited by 9
The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines
Lin, X., Xiang, H., Wu, J., Liao, R., Li, Y., Xu, B., Xu, Y., Shen, Y., Li, Q., & Tian, Y. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101121 · Cited by 14
Gearing up for battle: Harnessing adaptive T cell immunity against gram-negative pneumonia
Gao, C. A., Morales‐Nebreda, L., & Pickens, C. I. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934671 · Cited by 9
Zhang, X., Jozić, A., Song, P., Xu, Q., Shi, X., Wang, H., Bishop, L., Struthers, H. M., Rutledge, J. C., Chen, S., et al. (2023) · Rheumatology and Immunology Research · doi:10.2478/rir-2023-0013 · Cited by 9
Lescoat, A., Kato, H., & Varga, J. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000970 · Cited by 10
Advanced cell and gene therapies in cardiology
Carvalho, A. B., Kasai-Brunswick, T. H., & de Carvalho, A. C. C. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105125 · Cited by 9
Bates, S. M., Evans, K. V., Delsing, L., Wong, R., Cornish, G. H., & Bahjat, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104239 · Cited by 11
Guo, Q., Li, J., Wang, J., Li, L., Jia, W. P., & Zhang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1502298 · Cited by 10
Self-citationImmuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies
Miao, M., Liu, X., Zhang, H., & Dai, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1516977 · Cited by 11
HIV Tat as a latency reversing agent: turning the tables on viral persistence
Fisher, B. M., Cevaal, P. M., Roche, M., & Lewin, S. R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571151 · Cited by 10
T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR
Vagnozzi, R. J., & McKinsey, T. A. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.02.002 · Cited by 10
Rejuvenation Strategy for Inducing and Enhancing Autoimmune Response to Eliminate Senescent Cells
Wang, X., Zhang, C., Su, J., Ren, S., Wang, X., Zhang, Y., Yuan, Z., He, X., Wu, X., Li, M., et al. (2025) · Aging and disease · doi:10.14336/ad.2024.0579 · Cited by 8
Emerging approaches for T cell-stimulating platform development
Ariail, E. C., Espinoza, N. G., Stephenson, A. C., & Spangler, J. B. (2024) · Cell Systems · doi:10.1016/j.cels.2024.11.007 · Cited by 10
T Cell-Targeting Nanotherapies for Atherosclerosis
Lambaren, K., Trac, N. T., Fehrenbach, D. J., Madhur, M. S., & Chung, E. J. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00590 · Cited by 8
Regulatory T cell therapy in autoimmune liver disease and transplantation
Fleming, M., Fueyo, A. S., & Safinia, N. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101394 · Cited by 14
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging
Zhang, N., Seo, J. W., Robinson, E. R., Rivera‐Rodriguez, A., Wang, J., Guo, Y., Czerwinski, D. K., Kim, H. R., Tumbale, S. K., Raie, M. N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504950122 · Cited by 15
Ferro, A., Segreti, A., Crispino, S. P., Cricco, R., Cristo, A. D., Ciancio, M., Gurrieri, F., Ussia, G. P., & Grigioni, F. (2025) · Genes · doi:10.3390/genes16070801 · Cited by 10
Microsystem technologies for accelerating the discovery and translation of immunotherapies
Wang, Z., Liu, C. Y., Chen, K., Song, J. W., & Kelley, S. O. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01268-4 · Cited by 12
CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis
Xu, L., Du, Z., Zhang, Y., Lv, X., Zhang, C., & Li, D. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115840 · Cited by 9
Zhang, W., Duan, L., Wang, C., Liao, Y., Zhao, R., Li, Z., Zhang, H., Wang, Z., & Zhang, J. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.12.007 · Cited by 10
Zuo, M., Wang, J., Zhang, W., Xiao, L., Qiao, Z., Li, W., Zhao, J., Xiong, K., Yan, X., & Zhang, K. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217388 · Cited by 8
CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming
Wang, M. R., Mu, W., Zhen, A., & Kitchen, S. G. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.12.001 · Cited by 10
TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy
Gao, J., Yang, Z., Song, Y., Shao, L., Dong, X., Li, Y., Bo, L., Zhao, X., Han, M., Tang, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69858-3 · Cited by 11
Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells
Li, T., Luo, R., Su, L., Lv, F., Mei, L., & Yu, Y. (2023) · Small Methods · doi:10.1002/smtd.202300880 · Cited by 8
Encapsulating In Vitro Transcribed circRNA into Lipid Nanoparticles Via Microfluidic Mixing
Juchem, M., Cushman, S., Lu, D., Chatterjee, S., Bär, C., & Thum, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3678-7_14 · Cited by 8
Current experimental and early investigational agents for cardiac fibrosis: where are we at?
Ciampi, C. M., Sultana, A., Ossola, P., Farina, A., Fragasso, G., & Spoladore, R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326024 · Cited by 8
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
Sun, W., Wu, Y., & Ying, T. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105867 · Cited by 9
Advancing in vivo reprogramming with synthetic biology
Islam, F., Lewis, M. R., Craig, J. D., Leyendecker, P. M., & Deans, T. L. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103109 · Cited by 8
Jia, R., Lu, J., Sun, B., Zhang, K., Wang, N., Wen, Y., & Ma, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135654 · Cited by 10
RetractedAllogeneic and other innovative chimeric antigen receptor platforms
Jallouk, A. P., Sengsayadeth, S. M., Savani, B. N., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.121404 · Cited by 9
Liang, X., Liu, S., Liu, G., Fan, Q., Ma, F., Yin, Y., Li, Z., Wu, Y., & Zheng, M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05737-2 · Cited by 9
Tocchetti, C. G., González, A., Backs, J., Pollesello, P., Rainer, P. P., Schiattarella, G. G., Bellin, M., Begley, G., Bock-Marquette, I., Balligand, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3709 · Cited by 8
Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics
Geddie, M. L., Kirpotin, D. B., Kohli, N., Kornaga, T., Boll, B., Razlog, M., Drummond, D. C., & Lugovskoy, A. A. (2022) · mAbs · doi:10.1080/19420862.2022.2083466 · Cited by 8
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
Smole, A. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0049 · Cited by 9
Modulation of immune cells with mRNA nanoformulations for cancer immunotherapy
Han, J., & Park, J. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103014 · Cited by 8
Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity
Lu, Y., Liu, X., & You, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102129 · Cited by 9
Nucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming
Balcorta, H. V., Guerrero, V., Bisht, D., & Poon, W. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00886 · Cited by 9
Immuno-cardio-oncology: Killing two birds with one stone?
Linthout, S. V., & Volk, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018772 · Cited by 9
Does hand stiffness reflect internal organ fibrosis in diabetes mellitus?
Phatak, S. B., Ingram, J. L., Goel, P., Rath, S., & Yajnik, C. S. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1198782 · Cited by 10
Zhang, S., Lu, H., Zhang, H., Ding, X., Wu, Q., Lei, A., Kong, N., & Zhang, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.621821 · Cited by 8
Mohmand-Borkowski, A., & Rozmysłowicz, T. (2024) · Metabolites · doi:10.3390/metabo14110573 · Cited by 7
Esmaeilzadeh, A., Hadiloo, K., Yaghoubi, S., Makoui, M. H., & Mostanadi, P. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01056-7 · Cited by 8
The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
Ge, Z., Wu, Q., Lv, C., & He, Q. (2025) · Immunology · doi:10.1111/imm.13943 · Cited by 8
Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells
Trines, M. M., Hoorn, D., Hofstraat, S. R. J., Zwolsman, R. C., Anbergen, T., Versteeg, I., van Elsas, Y., Deckers, J., Hendrikx, M., Kleuskens, T., et al. (2025) · Advanced Materials · doi:10.1002/adma.202504830 · Cited by 11
ANTXR1 blockade enhances cardiac function in preclinical models of heart failure
Boccella, N., Yu, G., Seaman, S., Feng, Y., Lee, J., Tomassoni‐Ardori, F., Yang, L., Hsu, K.-S., Dunleavey, J. M., Becker, J., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00725-y · Cited by 8
Cell therapy for Duchenne muscular dystrophy: promises, challenges, and controversies
Łoboda, A., & Dulak, J. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05904-5 · Cited by 8
Redefining multiple sclerosis with CAR-T cell therapy
Li, Y.-R., Chen, Y., & Yang, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.022 · Cited by 8
Targeting strategies, clinical translation and translational barriers of liposomes in cancer therapy
Su, J., Na, J., Yang, Q., Huang, H., Xiao, L., Wu, P., & Zhong, L. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153155 · Cited by 9
An inhalable liquid-core lipid nanoplatform enables macrophage-mediated mRNA delivery to lung tumors
Liu, C., Zhang, Z., Yuan, Y., Wang, H., Guan, J., & Mao, S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114601 · Cited by 8
Guo, Z., Zhang, M., & Huang, Y. (2026) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100040 · Cited by 7
Nanozymes for inflammatory disease therapy: ROS homeostasis and clinical prospects
Chen, X., Zhan, Y., Fan, X., Pan, J., Lv, Y., Wang, W. E., Jiang, W., Liu, Y., & Tang, J. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173836 · Cited by 12
Toward In Vivo CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design
Sciuto, L., Kooijmans, S. A. A., & Schiffelers, R. M. (2026) · Nano Letters · doi:10.1021/acs.nanolett.5c05535 · Cited by 7
Han, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 10
Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics
Liu, D., Chen, H., Pan, A., & Wang, X. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00347 · Cited by 11
In vivo CAR T cell engineering: design principles and open questions
Aalipour, A., Barreiro, A. E., Garmilla, A., & Birnbaum, M. E. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.01.007 · Cited by 10
Zhao, W., Xin, Z. H. O. U., Zhao, X., Tian, H., Su, Y., Zhao, S., Liu, M., Zhang, Q., Lin, C., Li, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102698 · Cited by 7
Self-citationCAR-neutrophils produced in vivo to treat glioma
Chang, Y., Shao, K., Li, H., Jin, G., Bentley, R. T., McCain, R. R., Crain, C. J., Shen, J., Tan, Y., Liang, P.-Y., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01656-0 · Cited by 12
Ascendancy of semi-synthetic biomaterials from design towards democratization
Speidel, A. T., Grigsby, C. L., & Stevens, M. M. (2022) · Nature Materials · doi:10.1038/s41563-022-01348-5 · Cited by 10
Amoêdo‐Leite, C., Parv, K., Testini, C., Hidalgo, C. H., Xu, F., Giraud, A., Malaquias, M., Fasterius, E., Holl, D., Seignez, C., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00478-0 · Cited by 10
Chen, Z., Hu, Y., & Mei, H. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.017 · Cited by 7
Cancer Development and Progression in Patients with Heart Failure
Seuthe, K., Picard, F. S. R., Winkels, H., & Pfister, R. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00680-y · Cited by 8
Ahmad, A. A., Ghim, M., Kukreja, G., Neishabouri, A., Zhang, Z., Li, J., Salarian, M., Toczek, J., Gona, K. B., Hedayatyanfard, K., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268832 · Cited by 8
RNA-lipid nanoparticle therapeutics for women’s health
Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 7
Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis
Montano-Peguero, Y., Verdejo, H., Riquelme, J. A., Kogan, M. J., & Lavandero, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s520967 · Cited by 7
Transcriptional plasticity of fibroblasts in heart disease
Micheletti, R., & Alexanian, M. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210864 · Cited by 7
Milestone Papers on Signal Transduction Mechanisms of Hypertension and Its Complications
Eguchi, S., Torimoto, K., Adebiyi, A., Kanthakumar, P., Bomfim, G. F., Wenceslau, C. F., Dahlen, S. A., & Osei‐Owusu, P. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.21365 · Cited by 7
Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection
Meng, F., Fu, Y., Xie, H., & Wang, H. (2024) · Transplantation · doi:10.1097/tp.0000000000005025 · Cited by 8
Molecular Imaging of Heart Failure: An Update and Future Trends
Saraste, A., Ståhle, M. R., Roivainen, A., & Knuuti, J. M. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.03.005 · Cited by 7
Innovative cell therapies for systemic sclerosis: available evidence and new perspectives
Lescoat, A., Ghosh, M., Kadauke, S., & Khanna, D. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2402494 · Cited by 7
Liuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac090 · Cited by 7
RNA-based nanomedicines and their clinical applications
Su, L.-J., Ji, Z.-H., Xu, M.-X., Zhu, J.-Q., Chen, Y., Qiao, J.-F., Wang, Y., & Lin, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6238-5 · Cited by 7
Disrupting off-target Cas9 activity in the liver
Dilliard, S. A., & Siegwart, D. J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00848-8 · Cited by 8
Editorial: Immunomodulatory Approaches in Cardiovascular Diseases
Booz, G. W., Altara, R., & Zouein, F. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.873452 · Cited by 7
Künzel, S. R., Klapproth, E., Zimmermann, N., Kämmerer, S., Schubert, M., Künzel, K., Hoffmann, M., Drukewitz, S., Vehlow, A., Eitler, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74206-w · Cited by 7
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
Mainkar, G., Ghiringhelli, M., & Zangi, L. (2025) · Drugs · doi:10.1007/s40265-025-02173-1 · Cited by 7
CD8+T cell exhaustion: the potential for treating autoimmune diseases
Xu, Y., Yi, X., Li, C., & Chen, J. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102600 · Cited by 6
RNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research
Ferreira, D., & Rodrigues, L. R. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500082 · Cited by 7
Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons
Dong, L., Wang, J., & Xia, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-62981-7 · Cited by 8
Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects
Yang, M., Wu, S., Zhang, J., Lu, L., Deng, D., Xia, Q., Lovell, J. F., Shi, X., & Jin, H. (2025) · Research · doi:10.34133/research.0866 · Cited by 11
Sun, X., Sigal, S., Cosma, M.-A., Villiers, C. D., Weinberger, M., & Riley, P. R. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-025-00430-1 · Cited by 5
Optimizing the targeting of lipid nanoparticles for gene therapy
Yue, L., Gao, X., Qi, W., Zhang, L., & Wang, Y. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00351b · Cited by 8
Ma, P., Ma, H., Li, J., Bi, W., Zhang, S., Hou, W., & Xu, H. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104532 · Cited by 6
From bench to body: In vivo CAR engineering in the clinic
Li, Y.-R., & Yang, L. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102337 · Cited by 6
Genetically Encoded DNA Origami for CAR-T-Based Immunotherapy
Fan, J., Liu, H., Yang, C., Li, D., Zhu, H., Li, X., Wang, H., Ding, B., & Liu, J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c04782 · Cited by 7
Modified mRNA-Based Therapeutic Strategies for Myocardial Ischemia–Reperfusion Injury
Cai, T., & Yang, X.-Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010055 · Cited by 6
CD44-targeted lipid nanoparticles for enhanced CRISPR/Cas9 delivery in cancer gene editing
Zeng, Y., Zhao, G., Wu, S., Bochuan, H., Forn‐Cuní, G., Knol, R. A., Ghalbzouri, A. E., Snaar-Jagalska, E. B., & Kros, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114598 · Cited by 7
mRNA technology for the prevention and treatment of HIV-1 infection
Chuang, L. I. U., Yaremenko, A. V., Li, X., You, X., Zhu, X., Liu, N., Chen, W., Kong, N., Xie, T., Gaiha, G. D., et al. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00387-2 · Cited by 9
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.